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Objective: We have previously reported that an HLA 8 of 8
allele-matched unrelated donor (8/8 MUD) is superior to
a related donor with HLA-1 antigen mismatch in the graft-
versus-host (GVH) direction (RD/1AG-MM-GVH) in trans-
plantation for leukemia (Kanda J, et al. Blood 2012). However,
the risk of relapse during the unrelated donor coordination
period biases this comparison. Therefore, we performed
decision analysis of donor selection in allogeneic stem cell
transplantation for acute myeloid leukemia (AML) and acute
lymphoblastic leukemia (ALL) in ﬁrst remission (CR1); this
method can consider various factors including risk of relapse
during the donor coordination period and the decrease in
quality of life (QOL) as a result of chronic graft-versus-host
disease (GVHD).
Methods: The incidences of relapse during the coordination
period of 8/8MUD or RD/1AG-MM-GVH were estimated
using the data from published studies on chemotherapeutic
treatment for AML and ALL. Transition probabilities after
transplantation were estimated using the database of the
Transplant Registry Uniﬁed Management Program for the
Japan Society for Hematopoietic Cell Transplantation. The
expected 5-year survival probabilities with or without QOL
adjustments were estimated using TreeAgePro software.
One-way sensitivity analysis was performed by varying each
transition-probability value within its plausible range.
Results: In transplantation for AML-CR1, the expected 5-year
survival probability was higher on selection of 8/8MUD than
RD/1AG-MM-GVH (59% vs. 47%), and this superiority
remained unchanged by sensitivity analysis of various
factors, including the interval between achievement of CR1
and actually receiving transplantation. In transplantation for
ALL-CR1, the 5-year survival probability was higher on
selection of 8/8 MUD (48% vs. 43%). In one-way sensitivity
analysis, the 5-year survival probability was higher on
selection of RD/1AG-MM-GVH when the interval between
CR1 and 8/8 MUD transplantation was 7 months. However,
8/8 MUD was superior after QOL adjustments. If the 5-year
survival rate was increased by 3% (7% after QOL adjustment)
in transplantation using RD/1AG-MM-GVH, the merit of
selecting RD/1AG-MM-GVH outweighs that of 8/8 MUD.
Conclusions: 8/8MUDshouldbeprioritized in transplantation
for AML-CR1. In transplantation for ALL-CR1, RD/1AG-MM-
GVHshould beprioritized onlywhen the interval between CR1
and 8/8 MUD transplantation is expected to be long. However,
MUD should be prioritized if QOL is considered.476
Missing KIR-Ligands in Single Mismatched Unrelated
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gGmbH (IKT), Ulm, GermanyOccurrences of relapse and transplantation related mortality
(TRM) are major complications after allogeneic hematopoi-
etic stem cell transplantation (HSCT). In haploidentical
transplantation, mismatches for inhibitory killer cell immu-
noglobulin-like receptor (KIR)-ligand in GvHD direction have
been shown to be associated with lower rates of relapse.
To investigate a potential effect of NK alloreactivity as pre-
dicted by themissing ligandmodel in the setting of unrelated
transplantation, we investigated 496 patients transplanted
for malignant disorders with single HLA-B or HLA-C mis-
matched donors and T-cell-replete grafts. “Missing ligand”
was deﬁned as absence of a donor KIR ligand HLA-C group 1,2
or HLA-Bw4 allele in the patient in GvH-direction only or in
combined HvG/GvH direction. Overall survival (OS), disease
free survival (DFS), relapse, and treatment related mortality
(TRM)were assessed usingKaplan-Meier analysis, competing
risks regression and extended Cox regression models.
Out of the 496 transplantation pairs, 109 (22.0%) were iden-
tiﬁed as belonging to the “missing ligand”-group, the
remaining 387 (78.0%) were used as a control group. Univar-
iate and multivariate analysis did not show any differences
regarding OS or DFS between the two groups. Univariate
analysis showed no signiﬁcant difference regarding TRM
(31.6% vs. 21.1%, P¼ .13) anda signiﬁcant higher risk for relapse
(29.0% vs. 38.7%, P ¼ .048) in the “missing ligand” group.
Multivariate competing risks regressionshowednosigniﬁcant
difference for TRM (HR 0.76, CI 0.49-1.23, P ¼ .28) and a trend
towards increased rates of relapse (HR 1.49, CI 1.00e 2.20, P¼
.05) for the patients within the “missing ligand” group.
The results of this study do not conﬁrm previous results seen
in haploidentical HSCT. T-cell alloreactivity dominates over
NK cell alloreactivity and leads to a diminished reconstitu-
tion of KIR expression in T-cell-replete grafts and potentially
impaired “licensing” compared to T-cell depleted trans-
plantations. This effect could explain differences between
the haploidentical related and single mismatched unrelated
transplantation.
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Adoptive transfer of T cells directed to tumor-associated
antigens (TAAs) by transgenic expression of chimeric antigen
receptors (CARs) can produce tumor responses, even in
patients with resistant malignancies. However targeting
a single TAA may lead to selection of the nontargeted TAA
population, leading to tumor immune escape. To overcome
this limitation, we have targeted two distinct TAAs, MUC1
and PSCA, both commonly express in pancreatic cancer. We
ﬁrst constructed a CAR targeting MUC1, which coexpressed
a truncated form of CD19 (DCD19) as a selectable marker.
After retroviral transduction, primary T cells stably expressed
both transgenes (834% and 668%, CAR-MUC1 and DCD19,
respectively). CAR-MUC1 T cells were able to speciﬁcally kill
MUC1+ target cell lines, CAPAN1 and DU145, with no
recognition of MUC1- targets, 293T (355%, 234% and
32% speciﬁc lysis, respectively, 10:1 E:T). To further eval-
uate the longer term killing effects, we cultured theseMUC1+
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and found that >60% of CAPAN1 and >40% of DU145 were
killed after an initial treatment but were resistant to subse-
quent treatment. Importantly IHC analysis of these resistant
tumor cells demonstrated lack of expression of the targeted
antigen, MUC1. This observation was conﬁrmed in an artiﬁ-
cial model using 293T cells engineered to express either
MUC1 (mOrange+) or PSCA (GFP+), which illustrated an
exquisite speciﬁcity of T cells but at the same time a weak-
ness when targeting a heterogeneous tumor cell population.
Therefore we generated a second CAR targeting the TAA
PSCA, and demonstrated stable expression on primary T cells
(892%), whichwere able to kill the PSCA+ cell lines, CAPAN1
and DU145, with no effect on control PSCA- 293T, (486%,
4146% and 42% speciﬁc lysis, respectively, 10:1 E:T).
Finally, we assessed the anti-tumor effects when both CAR-
modiﬁed products were combined. When tumor cells
expressing both TAAs were treated with CAR-MUC1 + CAR-
PSCA T cells we saw additive anti-tumor effects with 7610%
killing of CAPAN1 compared with only 356% and 486%,
respectively, using CAR-MUC1 and CAR-PSCA T cells indi-
vidually. We saw similar results using our engineered 293T
tumormodel. Hence the combination of CARs that target two
distinct TAA expressed on cancer cells (PSCA andMUC1) may
prevent tumor immune escape and enhance the potency of
adoptive T cell transfer.478
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Background: Medulloblastoma is the most common brain
tumor in children and its prognosis is improved by the
combination of surgical resection, irradiation, and/or
chemotherapy. Chemotherapy followed by autologous
peripheral blood stem cell (auto-PBSC) rescue has been used
for the treatment of high-risk medulloblastoma.
Patients & Methods: Between July 2010 and July 2012, 8
patients with high-riskmedulloblastoma underwent tandem
chemotherapy with stem cell rescue procedures imple-
menting one of two protocols. Four children aged less than
36 months old [median age 30 month old (range 24-33
months old)] (group-A) received the Children's Oncology
Group e ACNS0334 protocol. The other 4 patients aged more
than 36 months old [median age 12 year old (range 9-15
years old)] (group-B) were treated according to the St. Jude -
SJMB03 protocol.
Results: All patients engrafted well and are alive with no
evidence of disease. Median follow-up from discharge for
last transplant is 6.5 months (range 3-24 months). Neither
cardio nor pulmonary toxicities were documented. Gastro-
intestinal tract: No patient had veno-occlusive disease of the
liver. All patients developed mild to moderate mucositis,
thus received total parentral nutrition for a median period of
7 days (range 5-12 days). Infections: group-A: all patients
experienced at least 1 transplant period without any fever.
Bacteremia included staphylococcus Coa. (-), proteus sp. and
pseudomonas sp. Neither viral nor fungal infections were
documented. Group-B: 2 patients experienced at least 1
transplant without any fever. Bacteremia included staphy-
lococcus Coa. (-), staphylococcus aureus and pseudomonassp. Metabolically: 2 group-B patients developed inappro-
priate anti-diuretic-hormone secretion. All patients devel-
oped mild hypomagnesaemia. Neurology: 1 group-B patient
developed generalized motor weakness attributed to MESNA
he received for the cytoxan. From then on, cytoxanwas given
without MESNA but with urinary catheterization and
hyperhydration. He also developed mastication movements
attributed to the resperidal he got, which was stopped with
improvement. No patient developedmajor bleeding. Renal: 1
group-A patient received VP-16 instead of carboplatine on
the ﬁrst transplant due to basic renal impairment. 1 group-B
patient suffered from renal impairment with GFR reduction
between 25%-50% of baseline following his ﬁrst transplant.
He also demonstrated grade-3 ototoxicity and thus received
only 50% cisplatin dose from the third transplant. Another 2
group-B patients suffered from grade 4 ototoxicity before
admission and therefore did not get cisplatin at all.
Conclusions: Tandem auto-PBSC transplants are feasible for
high-risk medulloblastoma pediatric patients, with excellent
engraftment and survival results and acceptable toxicities,
applying the ACNS0334 and SJMB03 protocols.479
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Adoptive T-cell immunotherapy for solid tumors though
promising has shown limited efﬁcacy in clinical studies. The
hindrance to achieving an objective and durable therapeutic
response is, in part, mediated by the dynamic nature of the
tumor and its complex microenvironment. Tumor-directed
therapies fail to eliminate components of the microenvi-
ronment, which can reinstate a tumorigenic milieu and
contribute to recurrence. Cancer associated ﬁbroblasts
(CAFs), the most preponderant cell type in the microenvi-
ronment, contribute to desmoplasia, tumor growth and
therapeutic resistance. CAFs express ﬁbroblast activation
protein alpha (FAP), a membrane bound serine protease, in
a number of a solid tumors making it an attractive immu-
notherapeutic target. We hypothesized that targeting CAFs
with FAP-speciﬁc T cells will destroy the 'tumor promoting
haven', resulting in signiﬁcant anti-tumor effects.
To test this hypothesis, we successfully generated FAP-
speciﬁc T cells using a second-generation chimeric antigen
receptor (CAR) speciﬁc for FAP. A prototypical CAR combines
the antigen speciﬁcity of an antibody with the signaling
function of a T-cell. The resulting genetically engineered FAP-
speciﬁc T cells recognized and killed human as well as
murine FAP-positive target cells ex vivo. FAP-speciﬁc T cells
also led to a signiﬁcant decrease of FAP-positive murine lung
stromal cells with a concomitant reduction in A549 lung
tumor growth and improved survial when administered
systemically into SCID mice. Targeting FAP-positive CAFs
alone, therefore induces a signiﬁcant anti-tumor response
indicative of its important role in tumor progression.
Finally, given the reciprocal relationship between tumor cells
and CAFs, we hypothesized that co-targeting these two
compartmentswould result in enhancedanti-tumor response
